Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis

C. Carlesi, L. Pasquali, S. Piazza, A. Lo Gerfo, E. Caldarazzo Ienco, R. Alessi, F. Fornai, G. Siciliano

Research output: Contribution to journalArticlepeer-review


Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and ultimately fatal neurodegenerative disorder of unknown aetiology that involves the loss of upper and lower motor neurons in the cerebral cortex, brainstem and spinal cord. Significant progress in understanding the cellular mechanisms of motor neuron degeneration in ALS has not been matched with the development of therapeutic strategies to prevent disease progression, and riluzole remains the only available therapy, with only marginal effects on disease survival. More recently alterations of mRNA processing in genetically defined forms of ALS, as those related to TDP-43 and FUS-TLS gene mutations have provided important insights into the molecular networks implicated in the disease pathogenesis. Here we review some of the recent progress in promoting therapeutic strategies for neurodegeneration.

Original languageEnglish
Pages (from-to)151-167
Number of pages17
JournalArchives Italiennes de Biologie
Issue number1
Publication statusPublished - 2011


  • Amyotrophic lateral sclerosis
  • Clinical trial
  • Therapeutic strategies

ASJC Scopus subject areas

  • Medicine(all)
  • Cell Biology
  • Physiology


Dive into the research topics of 'Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this